Potential Public Health Impacts Of The Use Of Recombinant Bovine Somatotropin In Dairy Production
Table 1. Results from eight studies on the levels of IGF-1 in milk from rbGH-treated and untreated cows.
|
Company |
Author, Year of Publication |
Sample size (# of cows) |
rbGH dosage (Amount, duration) |
Equivalent dose (mg/14 day period |
Length of experiment (days) |
IGF-1 levels in milk increased |
|
American Cyanimid |
Schingoethe & Cleale, 1989 |
20 |
10.3 mg/14 day |
144 |
113 |
N |
|
Elanco |
Schames & Karg, 1988 |
8 |
640 mg/28 days |
320 |
118 |
Y |
|
Elanco |
Davis et. al, 1989 |
36 |
320 mg or 640 mg/28 days |
160 or 320 |
30 |
N |
|
Elanco |
Coleman et. al, 1990 |
12 |
640 mg/28 days |
320 |
56 |
N |
|
Monsanto |
FDA, 1993 |
18 |
500 mg/14 days |
500 |
42 |
Y |
|
Monsanto |
Torkelson et. al, 1988 |
18 |
500 mg/14 days |
500 |
42 |
Y |
|
Monsanto |
White et al., 1969 |
18 |
500 mg/14 days |
500 |
42 |
Y |
|
Monsanto |
Miller, et. al, 1989 |
64 |
500 mg/14 days |
500 |
140 |
Y |
Table 2. Effect of POSILAC on mastitis. Data from Kronfeld, 1997.
|
Period and parity |
Mastitis cases/100 cows/252 days |
Significance (p value) |
|
|
Control |
Posilac |
||
|
Pre-approval |
|||
|
…Primiparous |
21 |
37 |
0.015 |
|
…Multiparous |
36 |
54 |
0.0021 |
|
…All |
32 |
49 |
0.0001 |
|
*PAMP |
|||
|
…Primiparous |
27 |
33 |
0.17 |
|
…Multiparous |
44 |
59 |
0.0001 |
|
…All |
37 |
49 |
0.0001 |
|
*Post-approval monitoring program |
|||
Part 1 – Report
Part
1b – Report Continued
Part
2 – References
Part 3 – Tables